Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01877642 · ClinicalTrials.gov registry record · Phase 4
ADASUVE-Lorazepam Drug-Drug Interaction
A Phase 4 study, sponsored by Alexza Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT01877642 is a Phase 4 study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT01877642, a Phase 4 study, has completed, sponsored by Alexza Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study will compare the safety and effects over time for giving both ADASUVE and lorazepam (intramuscular) compared to that of each agent given alone.
Interventions
- DRUG Inhaled Placebo
- DRUG Inhaled loxapine 10 mg
- DRUG Lorazepam 1 mg IM
- DRUG Placebo IM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01877642
The ClinicalTrials.gov registry entry for NCT01877642 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexza Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Inhaled Placebo is the first listed.
NCT01877642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01877642 about?
NCT01877642 is a clinical study titled "ADASUVE-Lorazepam Drug-Drug Interaction". This study will compare the safety and effects over time for giving both ADASUVE and lorazepam (intramuscular) compared to that of each agent given alone.
What is the current status of trial NCT01877642?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2013-06. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01877642?
The interventions under investigation include: Inhaled Placebo (DRUG), Inhaled loxapine 10 mg (DRUG), Lorazepam 1 mg IM (DRUG), Placebo IM (DRUG).
Who is sponsoring clinical trial NCT01877642?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.